NICE opens consultation on nirogacestat for desmoid tumours
NICE has opened consultation on draft guidance for nirogacestat in desmoid tumours, marking an important stage in the UK health technology appraisal process rather than a final decision. The guidance carries reference number TA1199 and was published on 14 October 2026, with the draft consultation document itself published on 8 May 2026. For clinicians, commissioners, and patient groups, the practical meaning is straightforward: the recommendation is still open to comment and may change before final guidance is issued.
The consultation window closes at 5pm on 1 June 2026. NICE is asking stakeholders to review the consultation document alongside the supporting evidence in the committee papers before submitting comments through the online version of the draft guidance. The agency also invites feedback on whether any part of the recommendations raises equality concerns, including issues related to race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy, or maternity.
This is not final guidance.
That single line defines the current status of the appraisal. The committee has not closed the discussion, and the recommendations in section 1 may change after consultation. Once the comment period ends, the appraisal committee will meet again, review the responses, and prepare the final draft guidance. In NICE terminology, that step is consequential because it determines whether the recommendation stands, shifts, or is refined before publication in its final form.
Why the consultation stage matters for a rare tumor appraisal
Desmoid tumours are not a common target for routine policy debates, which makes the structure of the NICE appraisal especially important. For uncommon conditions, access decisions often depend as much on the quality of the evidence review and the committee’s interpretation as they do on the underlying clinical need. A draft consultation is where unresolved questions can still be raised, including how the treatment fits within existing care pathways, what the evidence means for different patient groups, and whether any recommendations could unintentionally disadvantage people with protected characteristics.
NICE’s consultation process is deliberately formal. Commenters are asked to engage with the recommendations as written, then provide direct feedback in the online document. A downloadable PDF is available, but comments can only be made in the online version. That design keeps the consultation anchored to the actual wording under review, rather than informal discussion outside the process. It also means the consultation can capture practical concerns from clinicians, patients, and other stakeholders before the committee makes its final decision.
The focus on equality impact is not procedural decoration. In a rare disease appraisal, access, diagnosis, and treatment experience can vary substantially across patient groups, and NICE is explicitly asking whether the draft recommendations need particular consideration to avoid unlawful discrimination. Those questions sit alongside the clinical appraisal itself, because a recommendation that looks sound on paper can still create avoidable inequity in practice if implementation is uneven or if patient subgroups are not considered carefully.
The evidence package behind TA1199
NICE has made several supporting documents available with the draft consultation. These include the consultation document, the equality impact assessment, committee papers, and public committee slides. Each of those documents serves a different role in the appraisal, but together they form the material on which comments are based. The committee papers, in particular, are the window into how the appraisal has been framed and what evidence has been weighed.
For a clinician scanning the guidance page, the key point is that the assessment is still in motion. NICE has not provided final wording in this page, and no final recommendation should be assumed from the draft consultation alone. The drug name, indication, consultation status, and timeline are the only concrete elements available here, and they are sufficient to show that TA1199 is moving through the standard review pathway rather than appearing as a settled policy decision.
Practical implications for services and patients
In real-world terms, draft guidance can influence planning before final publication. Services preparing for a potential recommendation may begin to consider how patients would be identified, where treatment would sit in existing pathways, and what governance arrangements would be needed if the recommendation is adopted. At the same time, patient groups often use the consultation period to draw attention to lived experience, tolerability concerns, or access barriers that may not be obvious from committee papers alone.
The process also signals that NICE is treating the topic as one requiring careful public and professional input. That matters in a condition-specific appraisal, where the population is likely to be smaller and the evidence base more concentrated than in common chronic disease guidance. The consultation period gives the committee a final opportunity to assess whether the draft recommendation is proportionate to the evidence and workable across the NHS.
One detail in the page stands out for its administrative precision: the page was last updated on 14 October 2026, even though the consultation closure date listed is 1 June 2026. For readers interpreting the document, the important point is not the webpage mechanics but the state of the appraisal itself. The draft guidance remains a consultation document, not the final word.
NICE has also linked the guidance page to the broader appraisal process, including a section on how the health technology evaluation process works. That framework is essential here because it reminds readers that the consultation is one phase in a larger sequence. Draft recommendation, public comment, committee reconsideration, final guidance: the decision pathway is still unfolding, and the next committee meeting will determine whether the current draft survives intact or is revised before publication.